[go: up one dir, main page]

EA202191403A1 - Композиция с высокой концентрацией белка - Google Patents

Композиция с высокой концентрацией белка

Info

Publication number
EA202191403A1
EA202191403A1 EA202191403A EA202191403A EA202191403A1 EA 202191403 A1 EA202191403 A1 EA 202191403A1 EA 202191403 A EA202191403 A EA 202191403A EA 202191403 A EA202191403 A EA 202191403A EA 202191403 A1 EA202191403 A1 EA 202191403A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
protein concentration
high protein
compositions
methods
Prior art date
Application number
EA202191403A
Other languages
English (en)
Inventor
Хантер Чен
Эрика Шлезингер
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202191403A1 publication Critical patent/EA202191403A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к композициям и способам для получения композиций с высокой концентрацией терапевтического белка.
EA202191403A 2018-11-21 2019-11-21 Композиция с высокой концентрацией белка EA202191403A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770337P 2018-11-21 2018-11-21
PCT/US2019/062596 WO2020106948A1 (en) 2018-11-21 2019-11-21 High concentration protein formulation

Publications (1)

Publication Number Publication Date
EA202191403A1 true EA202191403A1 (ru) 2021-08-09

Family

ID=68916589

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191403A EA202191403A1 (ru) 2018-11-21 2019-11-21 Композиция с высокой концентрацией белка

Country Status (14)

Country Link
US (2) US12036280B2 (ru)
EP (1) EP3883542A1 (ru)
JP (1) JP7637618B2 (ru)
KR (1) KR20210093976A (ru)
CN (1) CN113164378A (ru)
AU (1) AU2019384160B2 (ru)
BR (1) BR112021009463A2 (ru)
CA (1) CA3118306A1 (ru)
EA (1) EA202191403A1 (ru)
IL (1) IL283229A (ru)
MX (1) MX2021005910A (ru)
SG (1) SG11202104166QA (ru)
WO (1) WO2020106948A1 (ru)
ZA (1) ZA202102816B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118948760A (zh) 2018-05-10 2024-11-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
WO2025043134A1 (en) * 2023-08-24 2025-02-27 Rezolute, Inc. High concentration formulations for anti-insulin receptor antibody and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1142172B (it) * 1978-10-19 1986-10-08 Sandoz Ag Nuovo impiego in terapeutica della ciclosporina-a e della diidrociclosporina-c
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
WO2002011695A2 (en) * 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
AU2012225277A1 (en) * 2011-03-10 2013-09-26 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
CN103356490A (zh) * 2012-03-29 2013-10-23 复旦大学 可直接固体化的交联食物蛋白稳定化纳米给药系统
TR201810930T4 (tr) * 2012-05-18 2018-08-27 Genentech Inc Yüksek konsantrasyonlu monoklonal antikor formülasyonları.
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
IL312865B1 (en) * 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
SMT202200464T1 (it) * 2014-05-06 2023-01-13 S I I T S R L Servizio Int Imballaggi Termosaldanti Formulazione oleosa erogabile tramite spray a base di vitamine liposolubili del gruppo d e relativo uso
WO2016109822A1 (en) * 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies

Also Published As

Publication number Publication date
MX2021005910A (es) 2021-08-16
CA3118306A1 (en) 2020-05-28
ZA202102816B (en) 2024-08-28
US12036280B2 (en) 2024-07-16
KR20210093976A (ko) 2021-07-28
SG11202104166QA (en) 2021-05-28
AU2019384160B2 (en) 2025-01-16
US20200155678A1 (en) 2020-05-21
AU2019384160A1 (en) 2021-05-27
CN113164378A (zh) 2021-07-23
JP7637618B2 (ja) 2025-02-28
US20240316195A1 (en) 2024-09-26
EP3883542A1 (en) 2021-09-29
JP2022532965A (ja) 2022-07-21
WO2020106948A1 (en) 2020-05-28
BR112021009463A2 (pt) 2021-08-10
IL283229A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2021014286A (es) Proteinas multiespecificas.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA201892147A1 (ru) Бициклические соединения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
EA201890572A1 (ru) Биофармацевтические композиции
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA202190810A1 (ru) Способы и наборы для получения цельной крови с инактивированным патогеном
EA201892203A1 (ru) Оксабороловые сложные эфиры, их применение
EA202191403A1 (ru) Композиция с высокой концентрацией белка
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA202190807A1 (ru) Антитела к синуклеину
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EA201890177A1 (ru) Мультиспецифические связывающие белки